Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Merck And Co Inc Drug Patent Portfolio

Merck And Co Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Merck And Co Inc News

Merck & Co., Inc. shares: A fundamental player in drug development and a dependable source of dividends for investors.

03 Apr, 2026

Lupin Challenges Merck! Generic Sugammadex Receives Tentative Approval from the US FDA

31 Mar, 2026

How Merck's Latest Cholesterol Treatment Aims to Make a Significant Impact by Eliminating Injections

30 Mar, 2026

Merck is close to finalizing a $6 billion deal to acquire Terns Pharma in order to enhance its cancer treatment offerings, according to the Financial Times.

26 Mar, 2026

See More